Substandard and Falsified Medicines Explained

The global medicine supply chain is vast and highly interconnected, linking raw material suppliers, manufacturing facilities, and distribution networks across multiple continents before a product finally reaches a patient. While this complex system successfully delivers life-saving treatments to billions of people, it also creates vulnerabilities. Medicines that are poorly manufactured, improperly stored, or deliberately fake pose a serious threat to public health. The World Health Organization (WHO) regularly monitors this issue, noting that people in low- and middle-income countries are disproportionately affected by products that fail to meet quality standards. Understanding the nature of these products is the first step toward safeguarding medicine quality.

Falsified Versus Substandard Medicines

It is common to hear the term "counterfeit" used to describe all bad medicines, but global regulators now prefer more precise terminology to distinguish between different types of failure. The WHO groups these under the umbrella term "Substandard and Falsified (SF) medical products". Substandard medicines are produced by legitimate manufacturers but fail to meet their own quality standards or specifications. This might happen due to manufacturing errors, poor-quality raw ingredients, or degradation from improper storage and transport. Falsified medicines, on the other hand, are deliberately and fraudulently misrepresented regarding their identity, composition, or source. They might contain no active ingredient, the wrong active ingredient, or even toxic substances, and are often packaged to look identical to genuine brands. A third category, unregistered medicines, are products that have not undergone evaluation or approval by the national regulatory authority of the country in which they are sold.

The Global Health Burden

The impact of SF medicines extends far beyond the individual patient who takes an ineffective pill. When medicines lack sufficient active ingredients, they fail to cure the intended disease, which prolongs illness and can increase mortality rates. Furthermore, consuming medicines with sub-therapeutic doses of antimicrobials—such as antibiotics or antimalarials—creates an environment where pathogens can survive and adapt. This drives the development and spread of drug-resistant infections, a threat that crosses borders and threatens global health security. There are also historical instances where falsified medicines contaminated with toxic substances used as inactive ingredients, such as diethylene glycol, have caused mass poisonings. The WHO estimates that approximately 1 in 10 medical products in low- and middle-income countries are substandard or falsified. The economic cost is also substantial, running into tens of billions of dollars annually, draining health system budgets and harming legitimate pharmaceutical manufacturers.

Track-and-Trace Supply Chain Systems

To combat falsified medicines, many governments and industry coalitions are implementing track-and-trace systems. These systems rely on a process called serialization, where every individual box or bottle of medicine is assigned a unique, randomized serial number. This number is printed on the packaging alongside a 2D data matrix barcode. As the product moves from the manufacturer to the wholesale distributor and finally to the pharmacy, the barcode is scanned at each step to verify its movement. This creates an electronic record, or pedigree, that confirms the product's origin and chain of custody. The European Union, for example, mandates verification at the point of dispensing through a centralized hub. Track-and-trace technologies make it significantly harder for falsified medicines to enter the legitimate supply chain and allow regulators to quickly identify and recall compromised batches.

Verifying Medicines Through Official Registries

Alongside physical tracking technologies, official medicine registries form a critical line of defense. National regulatory authorities maintain searchable databases of all medicines approved for sale within their specific jurisdictions. In South Africa, the South African Health Products Regulatory Authority (SAHPRA) is responsible for registering every legitimate medicine. Once registered, these products must also comply with the Single Exit Price (SEP) framework, which regulates the maximum price at which a medicine can be sold in the private sector. By searching a national registry, healthcare professionals and the public can verify that a product is legally approved, identify its legitimate manufacturer, and confirm its assigned registration number. Tools that aggregate and search these official regulatory databases, such as HealthSA, allow users to check the legitimacy of a medicine before purchase. If a product is not listed in the official registry, it may be an unregistered or falsified product.